Immunology
Autoimmunity
When self-tolerance fails — central and peripheral checkpoints, and the diseases that follow
Autoimmunity is an immune attack against the body's own tissues, occurring when central tolerance in the thymus and peripheral checkpoints fail. Lymphocytes that recognize self with high affinity should be deleted in the thymus (negative selection driven by AIRE-mediated self-antigen presentation) or held in check by regulatory T cells, anergy, and inhibitory receptors. Mutations in any of these systems — AIRE, FOXP3, CTLA-4 — produce monogenic autoimmunity. Polygenic autoimmune diseases involve hundreds of small-effect risk alleles plus environmental triggers, especially viral infections. About 4-8% of the population is affected, with women bearing roughly 80% of the disease burden.
- Population prevalence~4-8% globally
- Female-to-male ratio~3-4:1 overall
- Central tolerance geneAIRE (autoimmune regulator)
- Treg master regulatorFOXP3
- Common HLA associationHLA-B27 (ankylosing spondylitis), HLA-DR3/4 (T1D)
- Treatment targetsTNF, IL-6, IL-17, IL-23, B cells, JAK
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
Why autoimmunity matters
- Rheumatology. The discipline is largely defined by autoimmune disease — RA, lupus, vasculitides, spondyloarthropathies, myositis.
- Endocrinology. Type 1 diabetes, Hashimoto's, Graves', Addison's, and autoimmune polyglandular syndromes are all autoimmune.
- Neurology. Multiple sclerosis, myasthenia gravis, neuromyelitis optica, and autoimmune encephalitis define a major part of practice.
- Gastroenterology. Inflammatory bowel disease, celiac, autoimmune hepatitis, and primary biliary cholangitis are managed with immunomodulators.
- Dermatology. Psoriasis, vitiligo, alopecia areata, pemphigus, and lupus skin disease are autoimmune.
- Oncology. Checkpoint inhibitor adverse events recapitulate autoimmune disease and require similar management.
- Hematology. Autoimmune cytopenias (ITP, AIHA), antiphospholipid syndrome, and warm or cold antibodies all hinge on autoimmune mechanisms.
Common misconceptions
- "Autoantibody equals disease." Many healthy people have low-titer autoantibodies; clinical context determines significance.
- "Steroids cure autoimmunity." They suppress inflammation; long-term use causes osteoporosis, diabetes, infection, and cataracts.
- "Autoimmunity is one disease." Hundreds of distinct entities exist with different mechanisms, treatments, and prognoses.
- "Diet causes autoimmunity." Outside of celiac disease, dietary causation is not established despite popular claims.
- "Immunosuppression equals immunodeficiency." Modern targeted therapies reduce specific pathways with much smaller infection risk than legacy broad immunosuppression.
- "Autoimmunity is permanent." Some diseases remit (e.g., RA induced into low disease activity); B-cell depletion produces durable responses in subsets.
Frequently asked questions
What is self-tolerance?
The immune system's ability to discriminate self from non-self. Central tolerance occurs in the thymus (T cells) and bone marrow (B cells), where lymphocytes recognizing self-antigens with high affinity undergo apoptosis or receptor editing. AIRE drives ectopic expression of tissue-specific antigens in thymic epithelial cells so developing T cells can encounter and be deleted by self-antigens that exist outside the thymus. Peripheral tolerance catches cells that escape — through anergy, deletion, regulatory T cell suppression, and inhibitory receptors like CTLA-4 and PD-1.
How does autoimmunity start?
Most autoimmune disease involves both genetic susceptibility and an environmental trigger. HLA alleles are the strongest risk factors — HLA-B27 for ankylosing spondylitis, HLA-DR3/DR4 for type 1 diabetes, HLA-DR15 for multiple sclerosis. Viral infections often precede onset, possibly through molecular mimicry, bystander activation, or epitope spreading. Smoking is the strongest environmental risk for rheumatoid arthritis and multiple sclerosis. Vitamin D deficiency, gut microbiome composition, and stress are also implicated.
What's the spectrum of disease?
Organ-specific (type 1 diabetes attacking pancreatic beta cells, Hashimoto's thyroiditis, multiple sclerosis attacking CNS myelin, myasthenia gravis attacking acetylcholine receptors) versus systemic (lupus, rheumatoid arthritis, systemic sclerosis, vasculitides). Mechanisms include autoantibody-mediated destruction (autoimmune hemolytic anemia), receptor blockade or stimulation (myasthenia, Graves'), immune complex deposition (lupus nephritis), and T cell-driven cytotoxicity (type 1 diabetes, MS).
Why are women affected more?
X-chromosome dosage, sex hormones, and microchimerism all contribute. Estrogen generally promotes type 2 and humoral immunity; X-linked genes like FOXP3, CD40L, and TLR7 escape X-inactivation in some cells, raising effective dose. Pregnancy alters disease activity — rheumatoid arthritis often improves while lupus often worsens. Klinefelter syndrome (XXY men) carries lupus risk approaching that of XX women, supporting an X-dose mechanism.
What are the major treatments?
Glucocorticoids remain workhorses for acute flare control. Conventional DMARDs (methotrexate, hydroxychloroquine, azathioprine, mycophenolate) are immunomodulatory backbones. Biologics target specific cytokines: TNF inhibitors (adalimumab, infliximab) for RA and IBD; IL-6 receptor blockade (tocilizumab) for RA and giant cell arteritis; IL-17 (secukinumab) and IL-23 (guselkumab) for psoriasis and spondyloarthritis. B-cell depletion (rituximab) for vasculitis and refractory disease. JAK inhibitors (tofacitinib, baricitinib) for multiple indications. CAR-T cells against B cells are an emerging frontier in lupus.
What about immune checkpoint biology?
CTLA-4 and PD-1 are inhibitory receptors that maintain peripheral tolerance. Cancer immunotherapy with checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab) blocks these brakes to unleash anti-tumor responses. The expected price is autoimmune-like adverse events — checkpoint inhibitor colitis, hepatitis, hypophysitis, pneumonitis, and dermatitis are common. Severe events require immunosuppression. The same biology in reverse — engineering CTLA-4 fusion proteins (abatacept) — treats rheumatoid arthritis.
How is diagnosis confirmed?
Pattern of clinical disease plus characteristic autoantibodies. ANA screens for connective tissue disease; specific antibodies like anti-dsDNA and anti-Smith refine to lupus. Anti-CCP is sensitive and specific for rheumatoid arthritis. ANCAs distinguish vasculitis types. Anti-TPO and anti-thyroglobulin support thyroid autoimmunity. Anti-tTG is the screen for celiac disease. Tissue biopsy remains the gold standard for many — renal biopsy for lupus nephritis, salivary gland for Sjögren's, muscle for myositis.